These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 22867770

  • 1. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 2. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 3. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S, Gasparini R, Panatto D, Demarteau N.
    Gynecol Oncol; 2011 Jun 01; 121(3):514-21. PubMed ID: 21334734
    [Abstract] [Full Text] [Related]

  • 4. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA, Lepetic A, Demarteau N.
    BMC Public Health; 2014 Nov 26; 14():1222. PubMed ID: 25424716
    [Abstract] [Full Text] [Related]

  • 5. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.
    Curr Med Res Opin; 2008 May 20; 24(5):1473-83. PubMed ID: 18413014
    [Abstract] [Full Text] [Related]

  • 7. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.
    Vaccine; 2014 Feb 03; 32(6):733-9. PubMed ID: 24291200
    [Abstract] [Full Text] [Related]

  • 8. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH, Cheng WF, Jiang JH, You SL, Huang LW, Hsieh JY, Mukherjee P, Van Kriekinge G, Lee C.
    Asian Pac J Cancer Prev; 2019 May 25; 20(5):1377-1387. PubMed ID: 31127896
    [Abstract] [Full Text] [Related]

  • 9. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.
    Asian Pac J Cancer Prev; 2008 May 25; 9(3):459-66. PubMed ID: 18990021
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, Van Kriekinge G, Lee IH.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1158-1166. PubMed ID: 28075249
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.
    J Med Econ; 2010 Mar 04; 13(1):110-8. PubMed ID: 20085477
    [Abstract] [Full Text] [Related]

  • 12. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.
    BMC Public Health; 2017 Feb 02; 17(1):152. PubMed ID: 28148228
    [Abstract] [Full Text] [Related]

  • 13. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S, Zafar A, Saperi S, Amrizal M.
    Asian Pac J Cancer Prev; 2010 Feb 02; 11(6):1551-9. PubMed ID: 21338196
    [Abstract] [Full Text] [Related]

  • 14. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.
    BMC Infect Dis; 2013 Feb 07; 13():75. PubMed ID: 23390964
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L, Rémy V, Oyee J, Largeron N.
    Pharmacoeconomics; 2009 Feb 07; 27(3):231-45. PubMed ID: 19354343
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 17. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G, Sohn WY, Aljunid SM, Soon R, Yong CM, Chen J, Lee IH.
    Asian Pac J Cancer Prev; 2018 Apr 25; 19(4):933-940. PubMed ID: 29693347
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
    Cherif A, Ovcinnikova O, Palmer C, Engelbrecht K, Reuschenbach M, Daniels V.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2437703. PubMed ID: 39365579
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ.
    Eur J Cancer; 2010 Nov 01; 46(16):2973-85. PubMed ID: 20638840
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ, Tay SK, Teoh YL, Tok MY.
    BMC Public Health; 2011 Mar 31; 11():203. PubMed ID: 21453537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.